Federal Register - January 25, 2021
Version en texte Qu'est-ce que c'est?Dateas est un site Web indépendant, non affilié à un organisme gouvernemental. La source des documents PDF que nous publions est l'agence officielle indiquée dans chacun d'eux. Les versions en texte sont des transcriptions non officielles que nous faisons pour fournir de meilleurs outils d'accès et de recherche d'informations, mais peuvent contenir des erreurs ou peuvent ne pas être complètes.
Source: Federal Register
6892
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
Licensing Contact: To license this technology, please contact Carol A.
Salata at 2406273727; csalata@
niaid.nih.gov.
The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:
Dated: January 14, 2021.
Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Dated: January 8, 2021.
Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
Fields of Use Applying to Intellectual Property Group B
FR Doc. 202101487 Filed 12221; 8:45 am
FR Doc. 202101490 Filed 12221; 8:45 am BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Ziopharm Oncology, Inc. Ziopharm, headquartered in Boston, MA.
DATES: Only written comments and/or applications for a license which are received by the National Cancer Institutes Technology Transfer Center on or before February 9, 2021 will be considered.
SUMMARY:
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: 240 2765484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
jbell on DSKJLSW7X2PROD with NOTICES
Group B
E1732020: T Cell Receptors Recognizing R273C or Y220C
Mutation in P53
1. U.S. Provisional Patent Application 63/074,747, filed September 4, 2020
E17320200US01.
The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
Development, manufacture and commercialization of autologous, peripheral blood T cell therapy products engineered by transposon-mediated gene transfer to express T cell receptors reactive to mutated P53, as claimed in the Licensed Patent Rights, for the treatment of human cancers.
Specifically excluded from this field of use are CRISPR-engineered peripheral blood T cell therapy products for the treatment of human cancers.
Development, manufacture and commercialization of companion diagnostics approved or cleared by the FDA or equivalent foreign regulatory agency for Licensee-proprietary T cell therapy products.
Intellectual Property Group B is primarily directed to isolated TCRs reactive to mutated tumor protein 53
TP53 or P53, within the context of several HLAs. P53 is the archetypal tumor suppressor gene and the most frequently mutated gene in cancer.
Contemporary estimates suggest that >50% of all tumors carry mutations in P53. Because of its prevalence in cancer and its restricted expression to precancerous and cancerous cells, this antigen may be targeted on mutant P53expressing tumors with minimal normal tissue toxicity.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen 15 days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or objections.
Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.
License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C.
552.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment of Humans With Short Stature AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EpifiZa Inc. of Montreal, QC Canada.
DATES: Only written comments and/or applications for a license which are received by the National Cancer Institutes Technology Transfer Center on or before February 9, 2021 will be considered.
SUMMARY:
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior Technology Transfer Manager, National Institutes of Health, NCI Technology Transfer Center by email richard.girards@nih.gov or phone 2402766825.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property E0032014: Agents That Specifically Bind Matrilin3 and Their Use/Cartilage Targeting Agents and Their Use 1. United States Provisional Patent Application No. 61/927,904, filed 15
January 2014 HHS Reference No. E
00320140US01;
2. United States Patent No.
10,323,083, issued 18 June 2019 HHS
Reference No. E00320140US06;
3. United States Patent Application No. 16/391,101, filed 22 April 2019
E:FRFM25JAN1.SGM
25JAN1
